AAA receives orphan drug designation from FDA and EMA for Gallium-68 DOTATATE for use in patients with Gastro-Entero-Pancreatic Neuroendocrine Tumors
Martedì 04 Marzo 2014 14:22
PDF Stampa E-mail
Advanced Accelerator Applications (“AAA”) announced that they have received orphan drug designation status for their radiopharmaceutical, Gallium-68 DOTATATE.
The orphan drug designation has been granted by both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for use of Gallium-68 DOTATATE as a diagnostic agent for the management of Gastro-Entero-Pancreatic Neuroendocrine Tumors (GEP-NETs). The designation should foster rapid development of the agent for the benefit of GEP-NET patients in the U.S. and Europe.
Download the press release (4 March 2014) >>

Read more http://www.biopmed.eu/index.php?option=com_content&view=article&id=1638:aaa-receives-orphan-drug-designation-from-fda-and-ema-for-gallium-68-dotatate-for-use-in-patients-with-gastro-entero-pancreatic-neuroendocrine-tumors&catid=11:notizie&Itemid=12&lang=it